Management of Venous ThromboEmbolism in patients with acute leukemia at high bleeding risk: a multicenter study
- Authors: Napolitano, M.; Valore, L.; Malato, A.; Saccullo, G.; Vetro, C.; Enza Mitra, M.; Fabbiano, F.; Mannina, D.; Casuccio, A.; Lucchesi, A.; Del Principe, M.; Candoni, A.; Di Raimondo, F.; Siragusa, S.
- Publication year: 2015
- Type: Articolo in rivista (Articolo in rivista)
- Key words: Acute leukemia; Low Molecular Weight Heparin; Venous Thrombosis
- OA Link: http://hdl.handle.net/10447/127723
Abstract
In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. We performed a multicenter study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. We intended as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.5%. VTE occurred during chemotherapy in 17/22 (77.2%) cases, mainly (14/17, 82.3%) during the induction phase. Treatment of acute VTE was based on Low Molecular Weight Heparin (LMWH) at full dosage for the first month from diagnosis and reduced dosage (75%) for the following months.